FDA panel recommends testosterone therapy be more accessible to men, knocks ‘outdated’ restrictions

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ ...
MedPage Today on MSN

Expand labeling for testosterone replacement therapy, FDA panel says

Members of an FDA expert panel urged the agency to expand labeling for testosterone replacement therapy and remove its ...

Nasal spray sold nationwide recalled due to mold, ‘life-threatening' infections possible, FDA says

The voluntary recall of ReBoost Nasal Spray was issued Wednesday by MediNatura New Mexico, according to an announcement from ...
Becker's Hospital Review

FDA panel pushes to reclassify testosterone therapy

An FDA panel pushes reclassify testosterone therapy by recommending removal of controlled substance status and expanding treatment eligibility.
PharmiWeb

Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

Planned acquisition of brelovitug for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME ...